OncoSec Medical Incorporated (ONCS)
| Market Cap | 29.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -40.95M |
| Shares Out | 39.35M |
| EPS (ttm) | -1.06 |
| PE Ratio | n/a |
| Forward PE | 8.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,661 |
| Open | 0.770 |
| Previous Close | 0.734 |
| Day's Range | 0.730 - 0.770 |
| 52-Week Range | 0.670 - 4.250 |
| Beta | 1.97 |
| Analysts | Buy |
| Price Target | 7.65 (+935.3%) |
| Earnings Date | Jun 10, 2022 |
About ONCS
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinica...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ONCS stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 935.32% from the latest price.
News
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
PENNINGTON, N.J. and SAN DIEGO , April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...
OncoSec Announces Appointment of George Chi as Chief Financial Officer
PENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intra...
OncoSec Announces Changes to its Board of Directors
PENNINGTON, N.J. and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytok...
OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study
PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00...
OncoSec Provides Business Update
PENNINGTON, N.J. and SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytok...
5 Top Penny Stocks Analysts Say To Buy With 119%-430% Price Targets
5 Penny Stocks To Buy According To Analysts The post 5 Top Penny Stocks Analysts Say To Buy With 119%-430% Price Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....
OncoSec Provides Leadership Update
PENNINGTON, N.J. and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consisti...
OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian ...
Why Shares Of OncoSec Medical Are Trading Higher Today
OncoSec Medical (NASDAQ: ONCS) shares are trading higher after the company announced it entered into a Clinical Trial Collaboration and Supply Agreement with Merck to evaluate the combination of OncoSec...
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Co...
PENNINGTON, N.J. and SAN DIEGO, July 6, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration an...
OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer
PENNINGTON, N.J. and SAN DIEGO, June 24, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian Leu...
OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engi...
PENNINGTON, N.J. and SAN DIEGO, June 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice Presid...
OncoSec to Present at the Raymond James Human Health Innovation Conference
PENNINGTON, N.J. and SAN DIEGO, May 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at th...
OncoSec Appoints Robert M. Schinagl, Ph.D.
PENNINGTON, N.J. and SAN DIEGO, May 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Robert M.
OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Mel...
PENNINGTON, N.J. and SAN DIEGO, April 15, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral imm...
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Sol...
PENNINGTON, N.J. and SAN DIEGO, April 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral imm...
OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
PENNINGTON, N.J. and SAN DIEGO, March 25, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral can...
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotec...
OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining I...
PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, th...
OncoSec Medical Announces Proposed Public Offering of Common Stock
PENNINGTON, N.J. and SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing...
OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clini...
PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer ...
OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma...
PENNINGTON, N.J. and SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-695 regist...
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
PENNINGTON, N.J. and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapi...
OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus...
PENNINGTON, N.J. and SAN DIEGO, Aug.